Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab + Proton Therapy in R/M HNSCC
NCT03450967Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2018
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03450967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450967.